144例奥密克戎新型冠状病毒感染患者发病初期中医证候特征探讨Discussion on the Characteristics of Traditional Chinese Medicine Symptoms in 144 Patients with Novel Coronavirus Omicron Infection
张金荣,闵翼,时翠林,孙刚,刘义安
摘要(Abstract):
目的 探讨感染新型冠状病毒奥密克戎变异株患者的中医四诊及证候特征,为临床辨治提供参考。方法 对苏州地区确诊的144例感染新型冠状病毒奥密克戎变异株的患者进行中医证候调查,采集其基本信息、发病初期及入院时临床症状以及舌象、脉象等,并进行辨证分型。结果 144例患者中发病初期临床症状主要表现为咳嗽(42.36%)、咽部不适(36.11%)、发热(34.72%)、肢体酸痛(29.86%)、咯痰(25.69%)。入院时最常见中医症状排名前5位与发病初期时症状相仿,依次为咳嗽(41.67%),咽部不适(29.17%),咯痰(26.39%)、发热(23.61%),乏力(20.14%)。最常见舌象表现,舌色以淡白舌为主(65.28%),舌体多为胖舌(46.53%),部分患者有齿痕舌(19.44%),苔色多为白苔(86.81%),其中薄白苔最多(50.69%),其次为薄白腻苔(29.86%)。脉象以浮脉为主(72.92%),其中浮数脉(24.31%)、浮紧脉(23.61%)较多见。证候多见风寒湿毒表证,少数可见湿壅脾肺证、寒湿郁肺夹脾虚证(儿童)。结论 苏州地区新型冠状病毒肺炎患者的中医证候分布早期以上焦肺系病症为主,少数以中焦脾胃表现为主,“湿、毒”邪为主要病因,多见风寒湿表证、湿壅脾肺等证。
关键词(KeyWords): 新型冠状病毒肺炎;奥密克戎变异株;苏州;中医证候
基金项目(Foundation): 江苏省中医药管理局新型冠状病毒肺炎中医药防治应急研究专项(JSZYJ202201)
作者(Author): 张金荣,闵翼,时翠林,孙刚,刘义安
参考文献(References):
- [1]Paz M,Aldunate F,Arce R,et al.An evolutionary insight into severe acute respiratory syndrome coronavirus 2 omicron variant of concern[D].Virus Res,2022.
- [2]World Health Organization.Tracking SARS-Co V-2 variants[EB/OL].(2021-12-06)[2021-12-10].https://www.who.int/en/activities/tracking-SARS-Co V-2-variants/.
- [3]Cui Z,Liu P,Wang N,et al.Structural and functional characterizations of infectivity and immune evasion of SARS-Co V-2 Omicron[J].Cell,2022,185(5):860-871.
- [4]Maisa A,Spaccaferri G,Fournier L,et al.First cases of omicron in france are exhibiting mild symptoms,November2021-January 2022[J].Infect Dis Now,2022,52(3):160-164.
- [5]Espenhain L,Funk T,Overvad M,et al.Epidemiological characterisation of the first 785 SARS-Co V-2 Omicron variant cases in Denmark,December 2021[J].Euro Surveill,2021,26(50).
- [6]中华人民共和国国家卫生健康委员会.新型冠状病毒肺炎诊疗方案(试行第八版修订版)[J].中华临床感染病杂志,201,14(2):81-88.
- [7]江苏省新型冠状病毒肺炎中医辨治方案(试行第三版)[J].江苏中医药,2020,52(4):7-8.
- [8]Espenhain L,Funk T,Overvad M,et al.Epidemiological characterisation of the first 785 SARS-Co V-2 Omicron variant cases in Denmark,December 2021[J].Euro Surveill,2021,26(50).
- [9]Kozlov M.Omicron′s feeble attack on the lungs could make it less dangerous[J].Nature,2022,601(7892):177.
- [10]Abdullah F,Myers J,Basu D,et al.Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane,south africa[J].International Joural of Intectious Diseases,2021(116):38-42.
- [11]Zeng C,Evans JP,Qu P,et al.Neutralization and Stability of SARS-Co V-2 Omicron Variant[J].bio Rxiv,2021,12(16):472934.
- [12]Meo SA,Meo AS,Al-Jassir FF,et al.Omicron SARS-Co V-2new variant:global prevalence and biological and clinical characteristics[J].Eur Rev Med Pharmacol Sci,2021,25(24):8012-8018.
- [13]Peacock T,Brown J,Zhou J,et al.The SARS-Co V-2 variant,Omicron,shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry[J].Rrsearch gate,2022(1):647-651.
- [14]Hui K,Ho J,Cheung MC,et al.SARS-Co V-2 Omicron variant replication in human bronchus and lung ex vivo[J].Nature,2022,603(7902):715-720.
- [15]Arora S,Grover V,Saluja P,et al.Literature review of omicron:A grim reality amidst COVID-19[J].Microorganisms,2022,10(2):985-991.
- [16]孙宏源,毕颖斐,朱振刚,等.天津地区88例新型冠状病毒肺炎患者中医证候特征初探[J].中医杂志,2020,61(10):837-841.
- [17]郑芳萍,李娜芬,李晨瑶,等.基于真实世界研究厦门本土183例新型冠状病毒Delta变异株感染患者的临床特征及中医体质分布规律[J].中医药通报,2022,21(2):41-45.